These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 25132574

  • 1. Stromal microRNA-21 levels predict response to 5-fluorouracil in patients with pancreatic cancer.
    Donahue TR, Nguyen AH, Moughan J, Li L, Tatishchev S, Toste P, Farrell JJ.
    J Surg Oncol; 2014 Dec; 110(8):952-9. PubMed ID: 25132574
    [Abstract] [Full Text] [Related]

  • 2. dCK expression correlates with 5-fluorouracil efficacy and HuR cytoplasmic expression in pancreatic cancer: a dual-institutional follow-up with the RTOG 9704 trial.
    McAllister F, Pineda DM, Jimbo M, Lal S, Burkhart RA, Moughan J, Winter KA, Abdelmohsen K, Gorospe M, Acosta Ade J, Lankapalli RH, Winter JM, Yeo CJ, Witkiewicz AK, Iacobuzio-Donahue CA, Laheru D, Brody JR.
    Cancer Biol Ther; 2014 Jun 01; 15(6):688-98. PubMed ID: 24618665
    [Abstract] [Full Text] [Related]

  • 3. Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer.
    Hwang JH, Voortman J, Giovannetti E, Steinberg SM, Leon LG, Kim YT, Funel N, Park JK, Kim MA, Kang GH, Kim SW, Del Chiaro M, Peters GJ, Giaccone G.
    PLoS One; 2010 May 14; 5(5):e10630. PubMed ID: 20498843
    [Abstract] [Full Text] [Related]

  • 4. MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.
    Giovannetti E, Funel N, Peters GJ, Del Chiaro M, Erozenci LA, Vasile E, Leon LG, Pollina LE, Groen A, Falcone A, Danesi R, Campani D, Verheul HM, Boggi U.
    Cancer Res; 2010 Jun 01; 70(11):4528-38. PubMed ID: 20460539
    [Abstract] [Full Text] [Related]

  • 5. MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis.
    Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, Donahue TR.
    PLoS One; 2013 Jun 01; 8(8):e71978. PubMed ID: 23991015
    [Abstract] [Full Text] [Related]

  • 6. Plasma miR-181a-5p Downregulation Predicts Response and Improved Survival After FOLFIRINOX in Pancreatic Ductal Adenocarcinoma.
    Meijer LL, Garajová I, Caparello C, Le Large TYS, Frampton AE, Vasile E, Funel N, Kazemier G, Giovannetti E.
    Ann Surg; 2020 Jun 01; 271(6):1137-1147. PubMed ID: 30394883
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. MicroRNA expression as a predictive marker for gemcitabine response after surgical resection of pancreatic cancer.
    Ohuchida K, Mizumoto K, Kayashima T, Fujita H, Moriyama T, Ohtsuka T, Ueda J, Nagai E, Hashizume M, Tanaka M.
    Ann Surg Oncol; 2011 Aug 01; 18(8):2381-7. PubMed ID: 21347785
    [Abstract] [Full Text] [Related]

  • 9. Keratin 17 is a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma.
    Delgado-Coka LA, Roa-Peña L, Babu S, Horowitz M, Petricoin EF, Matrisian LM, Blais EM, Marchenko N, Allard FD, Akalin A, Jiang W, Larson BK, Hendifar AE, Picozzi VJ, Choi M, Shroyer KR, Escobar-Hoyos LF.
    Am J Clin Pathol; 2024 Sep 03; 162(3):314-326. PubMed ID: 38642081
    [Abstract] [Full Text] [Related]

  • 10. MicroRNA-10b expression correlates with response to neoadjuvant therapy and survival in pancreatic ductal adenocarcinoma.
    Preis M, Gardner TB, Gordon SR, Pipas JM, Mackenzie TA, Klein EE, Longnecker DS, Gutmann EJ, Sempere LF, Korc M.
    Clin Cancer Res; 2011 Sep 01; 17(17):5812-21. PubMed ID: 21652542
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cancer-Specific Targeting of Taurine-Upregulated Gene 1 Enhances the Effects of Chemotherapy in Pancreatic Cancer.
    Tasaki Y, Suzuki M, Katsushima K, Shinjo K, Iijima K, Murofushi Y, Naiki-Ito A, Hayashi K, Qiu C, Takahashi A, Tanaka Y, Kawaguchi T, Sugawara M, Kataoka T, Naito M, Miyata K, Kataoka K, Noda T, Gao W, Kataoka H, Takahashi S, Kimura K, Kondo Y.
    Cancer Res; 2021 Apr 01; 81(7):1654-1666. PubMed ID: 33648930
    [Abstract] [Full Text] [Related]

  • 15. A MicroRNA Signature Identifies Pancreatic Ductal Adenocarcinoma Patients at Risk for Lymph Node Metastases.
    Nishiwada S, Sho M, Banwait JK, Yamamura K, Akahori T, Nakamura K, Baba H, Goel A.
    Gastroenterology; 2020 Aug 01; 159(2):562-574. PubMed ID: 32376411
    [Abstract] [Full Text] [Related]

  • 16. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD, Fu ZQ, Lin Q, Zhou Y, Zhou QB, Li ZH, Tan LP, Chen RF, Liu YM.
    World J Gastroenterol; 2015 Aug 21; 21(31):9348-57. PubMed ID: 26309360
    [Abstract] [Full Text] [Related]

  • 17. Thymidylate synthase expression predicts the response to 5-fluorouracil-based adjuvant therapy in pancreatic cancer.
    Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi OP, Pitt HA, Ahrendt SA.
    Clin Cancer Res; 2003 Sep 15; 9(11):4165-71. PubMed ID: 14519641
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B, Liu X, Gao Y, Li L, Dong Z.
    Br J Biomed Sci; 2016 Oct 15; 73(4):152-157. PubMed ID: 27922430
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.